Search - tctmd.com

Displaying 141 - 160 of 332

Sort: Relevancy | Date

News Conference News CRT 2018

Wait Continues for a Win With Biodegradable-Polymer DES in Patients at High Bleeding Risk: BIO-RESORT

Michael O'Riordan

March 08, 2018

News Conference News CRT 2018

Early Low-Risk TAVR Data Reassure, but Durability Questions Remain

Michael O'Riordan

March 05, 2018

News Daily News

One-Third of TAVR and SAVR Patients Are Depressed, Upping Mortality Risk

L.A. McKeown

January 18, 2018

News Industry News

The Lancet Publishes Twelve-Month Results for DESSOLVE III Highlighting MiStent® Performance in All-Comers Randomized Trial

December 06, 2017

News Conference News AHA 2017

‘Acceptable Safety’ for LAA Closure Seen in a Real-World, All-Comers Registry

Todd Neale

November 22, 2017

News Daily News

Women, Minorities at Greater Risk for Non-Stent-Related Events After PCI

Yael L. Maxwell

October 20, 2017

News Daily News

Hormone Therapy Doesn’t Impact Long-term All-Cause, CV, or Cancer Mortality: WHI Analysis

Caitlin E. Cox

September 14, 2017

News Conference News VIVA 2017

DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease

L.A. McKeown

September 13, 2017

News Daily News

Real-World STEMI Study Shows Low Rate of Early Stent Thrombosis After Primary PCI

Todd Neale

July 28, 2017

News Daily News

TAVR Equivalent to Surgery in Real-World Practice, New Analysis Shows

Michael O'Riordan

July 17, 2017

News Conference News EuroPCR 2017

My Takeaways From EuroPCR 2017: Everything Perfect, Until It’s Not

Shelley Wood

June 02, 2017

News Conference News EuroPCR 2017

Scaffold Thrombosis ‘Unpredictable’ With Absorb: AIDA Analysis

Michael O'Riordan

May 19, 2017

News Conference News EuroPCR 2017

FFR-SEARCH Explores Potential of Physiologic Assessment After PCI

Caitlin E. Cox

May 18, 2017

News Conference News SCAI 2017

Minority Women Face 50% Increased Risk of Death/MI After PCI Compared With White Men at 1 Year

L.A. McKeown

May 18, 2017

News Conference News EuroPCR 2017

TAVR Durability: Some Reassurances From CoreValve Trials Out to 9 Years

Caitlin E. Cox

May 17, 2017

No Very Late Scaffold Thrombosis Risk With Absorb BVS in China, Japan

News Conference News EuroPCR 2017

No Very Late Scaffold Thrombosis Risk With Absorb BVS Studies in China, Japan

Michael O'Riordan

May 17, 2017

News Industry News

Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience

May 16, 2017

News Conference News EuroPCR 2017

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Michael O'Riordan

May 16, 2017

News Conference News SCAI 2017

Domo Arigato: High Success Rates, Low Radiation With Both Radial and Femoral Robotic PCI

L.A. McKeown

May 12, 2017

News Daily News

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

Michael O'Riordan

March 29, 2017

Advertisement

Wait Continues for a Win With Biodegradable-Polymer DES in Patients at High Bleeding Risk: BIO-RESORT

Early Low-Risk TAVR Data Reassure, but Durability Questions Remain

One-Third of TAVR and SAVR Patients Are Depressed, Upping Mortality Risk

The Lancet Publishes Twelve-Month Results for DESSOLVE III Highlighting MiStent® Performance in All-Comers Randomized Trial

‘Acceptable Safety’ for LAA Closure Seen in a Real-World, All-Comers Registry

Women, Minorities at Greater Risk for Non-Stent-Related Events After PCI

Hormone Therapy Doesn’t Impact Long-term All-Cause, CV, or Cancer Mortality: WHI Analysis

DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease

Real-World STEMI Study Shows Low Rate of Early Stent Thrombosis After Primary PCI

TAVR Equivalent to Surgery in Real-World Practice, New Analysis Shows

My Takeaways From EuroPCR 2017: Everything Perfect, Until It’s Not

Scaffold Thrombosis ‘Unpredictable’ With Absorb: AIDA Analysis

FFR-SEARCH Explores Potential of Physiologic Assessment After PCI

Minority Women Face 50% Increased Risk of Death/MI After PCI Compared With White Men at 1 Year

TAVR Durability: Some Reassurances From CoreValve Trials Out to 9 Years

No Very Late Scaffold Thrombosis Risk With Absorb BVS Studies in China, Japan

Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Domo Arigato: High Success Rates, Low Radiation With Both Radial and Femoral Robotic PCI

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content